RxDoctor Payments Data

Jason Lawrence, MD

Pulmonary Disease · Fishersville, VANPI 1477718922

Payments from drug & device makers

$5,883in general payments, 2019–2025

Across 53 payments — averaging $111.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Boehringer Ingelheim$1K
  • Johnson & Johnson$859
  • Regeneron Healthcare Solutions, Inc.$166
  • Abiomed$61
  • CSL Behring$20
  • plus $51 from 4 others

What the payments were for

  • Consulting fees$4,22572%
  • Travel & lodging$81114%
  • Food & beverage$80314%
  • Education$441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,883 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$111,550
Medicare patients
542
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter364$536,768
OfevNintedanib Esylate16$414,000
GlassiaAlpha-1-Proteinase Inhibitor26$381,119
Dupixent PenDupilumab30$111,895
XolairOmalizumab27$103,390
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$75,200
Breo ElliptaFluticasone/Vilanterol93$71,649
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr77$69,046
Spiriva HandihalerTiotropium Bromide29$30,647
Varenicline Tartrate89$23,822
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$22,145
Combivent RespimatIpratropium/Albuterol Sulfate16$21,567
SymbicortBudesonide/Formoterol Fumarate40$19,924
Spiriva RespimatTiotropium Bromide22$18,831
Albuterol Sulfate HfaAlbuterol Sulfate346$16,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$3,426$698,995566 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$1,300$476,54376 claims
AstraZenecaBreztri Aerosphere, Symbicort$12$95,12495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Fishersville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →